vs
Arthur J. Gallagher & Co.（AJG）与博士伦健康（BHC）财务数据对比。点击上方公司名可切换其他公司
Arthur J. Gallagher & Co.的季度营收约是博士伦健康的1.3倍（$3.6B vs $2.8B），Arthur J. Gallagher & Co.净利率更高（4.2% vs -3.7%，领先7.8%），Arthur J. Gallagher & Co.同比增速更快（33.6% vs 9.3%），Arthur J. Gallagher & Co.自由现金流更多（$713.4M vs $403.0M），过去两年博士伦健康的营收复合增速更高（14.0% vs 5.5%）
Arthur J. Gallagher & Co.（简称Gallagher）是总部位于美国伊利诺伊州芝加哥郊区罗林梅多斯的保险经纪及风险管理服务提供商，核心业务涵盖保险经纪、风险管理服务，还依托自有理赔师团队处理工伤赔偿、机动车保险理赔等相关业务，在全球保险服务领域拥有较高知名度。
博士伦健康公司（Bausch Health）是一家业务多元化的北美跨国制药企业，全球总部位于加拿大魁北克省拉瓦尔，美国总部设在新泽西州布里奇沃特。公司专注于胃肠病、肝病、神经科、皮肤科、牙科、医疗美容等领域的药物研发、生产及销售，同时提供品牌药和仿制药产品，业务覆盖全球市场。
AJG vs BHC — 直观对比
营收规模更大
AJG
是对方的1.3倍
$2.8B
营收增速更快
AJG
高出24.3%
9.3%
净利率更高
AJG
高出7.8%
-3.7%
自由现金流更多
AJG
多$310.4M
$403.0M
两年增速更快
BHC
近两年复合增速
5.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $3.6B | $2.8B |
| 净利润 | $151.1M | $-103.0M |
| 毛利率 | — | — |
| 营业利润率 | 5.0% | 17.0% |
| 净利率 | 4.2% | -3.7% |
| 营收同比 | 33.6% | 9.3% |
| 净利润同比 | -41.5% | -205.1% |
| 每股收益（稀释后） | $0.58 | $-0.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AJGBHC
| Q4 25 | $3.6B | $2.8B | ||
| Q3 25 | $3.4B | $2.7B | ||
| Q2 25 | $3.2B | $2.5B | ||
| Q1 25 | $3.7B | $2.3B | ||
| Q4 24 | $2.7B | $2.6B | ||
| Q3 24 | $2.8B | $2.5B | ||
| Q2 24 | $2.8B | $2.4B | ||
| Q1 24 | $3.3B | $2.2B |
净利润AJGBHC
| Q4 25 | $151.1M | $-103.0M | ||
| Q3 25 | $272.7M | $179.0M | ||
| Q2 25 | $365.8M | $148.0M | ||
| Q1 25 | $704.4M | $-58.0M | ||
| Q4 24 | $258.3M | $98.0M | ||
| Q3 24 | $312.6M | $-85.0M | ||
| Q2 24 | $283.4M | $10.0M | ||
| Q1 24 | $608.4M | $-64.0M |
营业利润率AJGBHC
| Q4 25 | 5.0% | 17.0% | ||
| Q3 25 | 10.3% | 23.1% | ||
| Q2 25 | 14.6% | 17.5% | ||
| Q1 25 | 23.4% | 12.2% | ||
| Q4 24 | 12.3% | 21.8% | ||
| Q3 24 | 14.4% | 12.7% | ||
| Q2 24 | 13.2% | 16.2% | ||
| Q1 24 | 23.7% | 13.1% |
净利率AJGBHC
| Q4 25 | 4.2% | -3.7% | ||
| Q3 25 | 8.1% | 6.7% | ||
| Q2 25 | 11.4% | 5.8% | ||
| Q1 25 | 18.9% | -2.6% | ||
| Q4 24 | 9.5% | 3.8% | ||
| Q3 24 | 11.1% | -3.4% | ||
| Q2 24 | 10.2% | 0.4% | ||
| Q1 24 | 18.7% | -3.0% |
每股收益（稀释后）AJGBHC
| Q4 25 | $0.58 | $-0.30 | ||
| Q3 25 | $1.04 | $0.48 | ||
| Q2 25 | $1.40 | $0.40 | ||
| Q1 25 | $2.72 | $-0.16 | ||
| Q4 24 | $1.10 | $0.24 | ||
| Q3 24 | $1.39 | $-0.23 | ||
| Q2 24 | $1.27 | $0.03 | ||
| Q1 24 | $2.74 | $-0.17 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $1.3B |
| 总债务越低越好 | $12.9B | $20.8B |
| 股东权益账面价值 | $23.3B | $-554.0M |
| 总资产 | $70.7B | $26.4B |
| 负债/权益比越低杠杆越低 | 0.55× | — |
8季度趋势，按日历期对齐
现金及短期投资AJGBHC
| Q4 25 | — | $1.3B | ||
| Q3 25 | — | $1.3B | ||
| Q2 25 | — | $1.7B | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | — | $1.2B | ||
| Q3 24 | — | $719.0M | ||
| Q2 24 | — | $595.0M | ||
| Q1 24 | — | $733.0M |
总债务AJGBHC
| Q4 25 | $12.9B | $20.8B | ||
| Q3 25 | — | $21.0B | ||
| Q2 25 | — | $21.7B | ||
| Q1 25 | — | $21.5B | ||
| Q4 24 | $23.0M | $21.6B | ||
| Q3 24 | — | $21.5B | ||
| Q2 24 | — | $21.7B | ||
| Q1 24 | — | $22.1B |
股东权益AJGBHC
| Q4 25 | $23.3B | $-554.0M | ||
| Q3 25 | $23.2B | $-565.0M | ||
| Q2 25 | $23.0B | $-764.0M | ||
| Q1 25 | $22.3B | $-1.2B | ||
| Q4 24 | $20.2B | $-1.3B | ||
| Q3 24 | $12.2B | $-1.2B | ||
| Q2 24 | $11.6B | $-1.2B | ||
| Q1 24 | $11.3B | $-1.1B |
总资产AJGBHC
| Q4 25 | $70.7B | $26.4B | ||
| Q3 25 | $79.1B | $26.8B | ||
| Q2 25 | $80.1B | $27.3B | ||
| Q1 25 | $74.1B | $26.4B | ||
| Q4 24 | $64.3B | $26.5B | ||
| Q3 24 | $57.2B | $26.5B | ||
| Q2 24 | $63.0B | $26.5B | ||
| Q1 24 | $61.0B | $26.9B |
负债/权益比AJGBHC
| Q4 25 | 0.55× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.00× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $753.0M | $495.0M |
| 自由现金流经营现金流 - 资本支出 | $713.4M | $403.0M |
| 自由现金流率自由现金流/营收 | 19.7% | 14.4% |
| 资本支出强度资本支出/营收 | 1.1% | 3.3% |
| 现金转化率经营现金流/净利润 | 4.98× | — |
| 过去12个月自由现金流最近4个季度 | $1.8B | $1.0B |
8季度趋势，按日历期对齐
经营现金流AJGBHC
| Q4 25 | $753.0M | $495.0M | ||
| Q3 25 | $731.3M | $405.0M | ||
| Q2 25 | $-426.1M | $289.0M | ||
| Q1 25 | $871.8M | $211.0M | ||
| Q4 24 | $739.3M | $601.0M | ||
| Q3 24 | $934.8M | $405.0M | ||
| Q2 24 | $119.5M | $380.0M | ||
| Q1 24 | $789.3M | $211.0M |
自由现金流AJGBHC
| Q4 25 | $713.4M | $403.0M | ||
| Q3 25 | $693.5M | $314.0M | ||
| Q2 25 | $-465.5M | $190.0M | ||
| Q1 25 | $843.6M | $96.0M | ||
| Q4 24 | $695.7M | $495.0M | ||
| Q3 24 | $898.0M | $334.0M | ||
| Q2 24 | $87.7M | $302.0M | ||
| Q1 24 | $759.6M | $129.0M |
自由现金流率AJGBHC
| Q4 25 | 19.7% | 14.4% | ||
| Q3 25 | 20.6% | 11.7% | ||
| Q2 25 | -14.5% | 7.5% | ||
| Q1 25 | 22.6% | 4.2% | ||
| Q4 24 | 25.6% | 19.3% | ||
| Q3 24 | 32.0% | 13.3% | ||
| Q2 24 | 3.2% | 12.6% | ||
| Q1 24 | 23.3% | 6.0% |
资本支出强度AJGBHC
| Q4 25 | 1.1% | 3.3% | ||
| Q3 25 | 1.1% | 3.4% | ||
| Q2 25 | 1.2% | 3.9% | ||
| Q1 25 | 0.8% | 5.1% | ||
| Q4 24 | 1.6% | 4.1% | ||
| Q3 24 | 1.3% | 2.8% | ||
| Q2 24 | 1.1% | 3.2% | ||
| Q1 24 | 0.9% | 3.8% |
现金转化率AJGBHC
| Q4 25 | 4.98× | — | ||
| Q3 25 | 2.68× | 2.26× | ||
| Q2 25 | -1.16× | 1.95× | ||
| Q1 25 | 1.24× | — | ||
| Q4 24 | 2.86× | 6.13× | ||
| Q3 24 | 2.99× | — | ||
| Q2 24 | 0.42× | 38.00× | ||
| Q1 24 | 1.30× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AJG
| Commissions | $2.1B | 57% |
| Broker Fees | $1.2B | 33% |
| Supplemental Revenue | $131.7M | 4% |
| Investment Performance | $121.8M | 3% |
| Contingent Revenue | $83.0M | 2% |
BHC
| Bausch Lomb | $1.4B | 50% |
| Salix Segment | $693.0M | 25% |
| International Rx | $306.0M | 11% |
| Diversified Segment | $255.0M | 9% |
| Solta Medical Segment | $137.0M | 5% |
